Please type a plus sign (+) in this box

+	

Page 1 of 4

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031

Approved for use through 9/30/00. OMB 0651-0031

Particular rademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Applicati n Number	09/662,783	RECE
	Filing Date	10/13/00	HEGEIVED
INFORMATION DISCLOSURE	First Named Inventor	Shimkets et al.	DEC
STATEMENT BY APPLICANT	Group Art Unit	1646	
	Examiner Name	Not Yet Assigned	TECHCO
(use as many sheets as necessary)	Attorney Docket Number	15966-577	TECH CENTER 1600/2300

Exam nitials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
PY	A1	4,816,567	3/28/89	Cabilly, et al.			
ì	A2	5,225,539	7/6/93	Winter			
	А3	5,545,807	8/13/96	Surani, et al.			
	A4	5,545,806	8/13/96	Lonberg, et al.			
	A5	5,569,825	10/29/96	Lonberg, et al.			
	A6	5,625,126	4/29/97	Lonberg, et al.			
	A7	5,939,598	8/17/99	Kucherlapati, et al.			
V	A8	5,916,771	6/29/99	Hori, et al.			

Exam Initlals	Cite No.	Forelo	gn Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
DX	B1	wo	96/41892	Mileham, et al.	12/27/96	
1	B2	wo	00/27879	Eriksson, et al.	5/18/00	
	В3	wo	94/02602	Kuncherlapati, et al.	2/3/94	
	B4	wo	96/33735	Kuncherlapati, et al.	10/31/96	
	B5	wo	96/34096	Kuncherlapati, et al.	10/31/96	
1/	В6	wo	99/53049	Davis, et al.	10/21/99	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
DY	CI	Alon, T., I. Hemo, et al. (1995). "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity." Nat Med 1(10): 1024-8.				
	C2	Athanassiades, A. and P. K. Lala (1998). "Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness." Placenta 19(7): 465-73.				
	C3	Bellamy, W. T., L. Richter, et al. (1999). "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies." Cancer Res 59(3): 728-33.				
	C4	Betsholtz, et al. (1986). "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines." Nature 320(6064): 695-9.				
V	C5	Bonthron, D. T., C. C. Morton, et al. (1988). "Platelet-derived growth factor A chain: gene structure, chromosomal location, and basis for alternative mRNA splicing." <u>Proc Natl Acad Sci U S A</u> 85(5): 1492-6.				

Applicants: Shimk ts et USSN 09/662,783

DEC 1 9 2000

OTHER PRIOR ART - NON PATENT LUCERATION DOCUMENTS Cite No. Exam Initials Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. Carmeliet, P., M. G. Lampugnani, et al. (1999). "Targeted deficiency or cytosolic truncation of the CHICENTER 1600/2900 VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis," Cell 98(2): 147-57. <u>C7</u> Collins, T., D. Ginsburg, et al. (1985). "Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis." Nature 316(6030): 748-50. C8 Cote, R. M., DM; Houghton, AN; Beattie, EJ; Oettgen, HF; Old, LJ (1983). "Generation of human monoclonal antibodies reactive with cellular antigens." Proc. Natl. Acad. Sci. USA 80: 2026-2030. <u>C9</u> Dalla-Favera, R., E. P. Gelmann, et al. (1981). "A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus." Nature 292(5818): 31-5. C10 Doolittle, R. F., M. W. Hunkapiller, et al. (1983). "Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor." Science 221(4607): 275-7. C11 Ferrara, N. (1999). "Vascular endothelial growth factor: molecular and biological aspects." Curr Top Microbiol Immunol 237: 1-30. C12 Fishwild, D. M., S. L. O'Donnell, et al. (1996). "High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice [see comments]." Nat Biotechnol 14(7): 845-51. C13 Folkman, J. (1995). "Angiogenesis in cancer, vascular, rheumatoid and other disease." Nat Med 1(1): C14 Gerber, H. P., A. McMurtrey, et al. (1998). "Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation." J Biol Chem 273(46): 30336-43. C15 Gerber, H. P., V. Dixit, et al. (1998). "Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells." J Biol Chem 273(21): 13313-6. Hamada, et al., 2000 "A novel gene derived from developing spinal cords, SCDGF, is a unique C16 member of the PDGF/BEFF family." FEBS Lett. 475(2): 970-102. GenBank Accession Number: BAB03265 C17 Helmlinger, et al. (2000). "Formation of endothelial cell networks." Nature 405(6783): 139-41. C18 Hermansson, M., M. Nister, et al. (1988). "Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation." Proc Natl Acad Sci U S A 85(20): 7748-52. C19 Holash, J., P. C. Maisonpierre, et al. (1999). "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF." Science 284(5422): 1994-8. C20 Hoogenboom, H. R. and G. Winter (1992). "By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro." J Mol Biol 227(2): 381-8. C21 Hopp, T. P. and K. R. Woods (1981). "Prediction of protein antigenic determinants from amino acid sequences." Proc Natl Acad Sci U S A 78(6): 3824-8. C22 Jones, P. T., P. H. Dear, et al. (1986). "Replacing the complementarity-determining regions in a human antibody with those from a mouse." Nature 321(6069): 522-5. C23 Josephs, S. F., C. Guo, et al. (1984). "Human-proto-oncogene nucleotide sequences corresponding to the transforming region of simian sarcoma virus." Science 223(4635): 487-91. C24 Katoh, M. and M. Terada (1996). "Overexpression of bone morphogenic protein (BMP)-4 mRNA in gastric cancer cell lines of poorly differentiated type." J Gastroenterol 31(1): 137-9. C25 Kelly, J. D., E. W. Raines, et al. (1985). "The B chain of PDGF alone is sufficient for mitogenesis." Embo J 4(13A): 3399-405. C26 Kessler, E., K. Takahara, et al. (1996). "Bone morphogenetic protein-1: the type I procollagen Cproteinase [see comments]." Science 271(5247): 360-2. C27 Kohler, G. and C. Milstein (1975). "Continuous cultures of fused cells secreting antibody of predefined specificity." Nature 256(5517): 495-7.



Page 3 of 4
RECEIVED

xam	Cite	Name of Author Title (when appropriate) Publication Volume Page (a) Page (b) Page (c)				
itials	No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.				
Re	C28	Kozbor, D. and J. Roder (1983). "The production of monoclonal antibodies from human lymphocytes." Immunology Today 4(3): 72-79. Kozbor, D. P. Tripputi, et al. (1984). "A hyman hybrid myslome for production of hyman				
<i>U</i> _	C29	lymphocytes." Immunology Today 4(3): 72-79.				
	(2)	1 Kozoo, D., 1. 111ppatt, et al. (1984). A numan hybrid myeloma for production of numan				
1	C30	monoclonal antibodies." J Immunol 133(6): 3001-5.				
	C30	Kyte, J. and R. F. Doolittle (1982). "A simple method for displaying the hydropathic character of a				
	C31	protein." J Mol Biol 157(1): 105-32.				
1	CSI	Li, et al., 2000 "PDGF-C is a novel protease-activated ligand for the PDGF alpha receptor." Nat. Cell				
+	C32	Biol. Direct Submission. GenBank Accession Number: AAF80597				
1	032	Li, J. M., J. S. Han, et al. (1999). "A novel gene delivery system targeting cells expressing VEGF receptors." Cell Res 9(1): 11-25.				
╂	C33	Lonberg, N. and D. Huszar (1995). "Human antibodies from transgenic mice." Int Rev Immunol				
		13(1): 65-93.				
+-	C34	Lonberg, N., L. D. Taylor, et al. (1994). "Antigen-specific human antibodies from mice comprising				
1		four distinct genetic modifications [see comments]." Nature 368(6474): 856-9.				
+	C35	Maeno, et al., 1993 "Cloning and expression of cDNA encoding Zenopus laevis bone morphogenetic				
1		protein-1 during early embryonic development." Gene 134(2): 257-261. GenBank Accession Number:				
		P98070				
+	C36	Marks, J. D., A. D. Griffiths, et al. (1992). "By-passing immunization: building high affinity human				
1		antibodies by chain shuffling." <u>Biotechnology (N Y)</u> 10(7): 779-83.				
+	C37	Marks, J. D., H. R. Hoogenboom, et al. (1991). "By-passing immunization. Human antibodies from				
İ		V-gene libraries displayed on phage." J Mol Biol 222(3): 581-97.				
+	C38	Marzo, I., C. Brenner, et al. (1998). "The central role of the mitochondrial megachannel in apoptosis:				
1		evidence obtained with intact cells, isolated mitochondria, and purified protein complexes." Biomed				
1		Pharmacother 52(6): 248-51.				
_	C39	Masood, R., J. Cai, et al. (1997). "Vascular endothelial growth factor/vascular permeability factor is				
Ì		an autocrine growth factor for AIDS-Kaposi sarcoma." Proc Natl Acad Sci U S A 94(3): 979-84.				
C40		Millauer, B., L. K. Shawver, et al. (1994). "Glioblastoma growth inhibited in vivo by a dominant-				
		negative Flk-1 mutant." Nature 367(6463): 576-9.				
	C41	Morrison, S. L. (1994). "Immunology. Success in specification [news; comment]." Nature 368: 812-3.				
	C42	Munson, P. J. and D. Rodbard (1980). "Ligand: a versatile computerized approach for characterization				
		of ligand-binding systems." Anal Biochem 107(1): 220-39.				
	C43	Neuberger, M. (1996). "Generating high-avidity human Mabs in mice [news; comment]." Nat				
- 1		Biotechnol 14(7): 826.				
	C44	Poltorak, Z., T. Cohen, et al. (1997). "VEGF145, a secreted vascular endothelial growth factor				
		isoform that binds to extracellular matrix." J Biol Chem 272(11): 7151-8.				
	C45	Riechmann, et al. (1988). "Reshaping human antibodies for therapy." Nature 332(6162): 323-7.				
	C46	Risau, W. (1995). "Differentiation of endothelium." Faseb J 9(10): 926-33.				
	C47	Risau, W. and I. Flamme (1995). "Vasculogenesis." Annu Rev Cell Dev Biol 11: 73-91.				
	C48	Rocchigiani, et al., 1998 "Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1				
		between the PIGA and the GRPR genes." Genomics 47: 207-216. GenBank Accession Number:				
		O43915				
	C49	Romashkova, J. A. and S. S. Makarov (1999). "NF-kappaB is a target of AKT in anti-apoptotic PDGF				
		signalling [see comments]." Nature 401(6748): 86-90.				
	C50	Shimizu, A., K. P. O'Brien, et al. (1999). "The dermatofibrosarcoma protuberans-associated collagen				
		type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming				
\perp		protein that is processed to functional PDGF- BB." Cancer Res 59(15): 3719-23.				
Τ,	C51	Simon, M. P., F. Pedeutour, et al. (1997). "Deregulation of the platelet-derived growth factor B-chain				
\mathbb{V}		gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell				
-	1	fibroblastoma." Nat Genet 15(1): 95-8.				



RECEIVED

DEC 22 2000

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	1600
P	C52	Speirs, V. and S. L. Atkin (1999). "Production of VEGF and expression of the VEGF receptors Flt-and KDR in primary cultures of epithelial and stromal cells derived from breast tumours." <u>Br J Cancer</u> 80(5-6): 898-903.	
1	C53	Tischer, E., R. Mitchell, et al. (1991). "The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing." J Biol Chem 266(18): 11947-54.	
	C54	Tsai, et al., 1998 "Fallotein, a novel growth factor like gene identified in human uterus." GenBank Accession Number: Q9UL22	
	C55	Tsai, et al., 1999 "cDNA cloning of fallotein from mouse ovary." GenBank Accession Number: Q9QY71	
	C56	Tsai, et al., 2000 "Identification of a novel platelet-derived growth factor-like gene, fallotein, in the human reproductive tract." Biochim. Biophys. Acta 1492(1) 196-202. GenBank Accession Number: AAF00049	
	C57	Tsai, et al., 2000 "Identification of a novel platelet-derived growth factor-like gene, fallotein, in the human reproductive tract." Biochim. Biophys. Acta 1492(1) 196-202. GenBank Accession Number: AF091434	
	C58	Verhoeyen, M., C. Milstein, et al. (1988). "Reshaping human antibodies: grafting an antilysozyme activity." Science 239(4847): 1534-6.	
	C59	Warren, R. S., H. Yuan, et al. (1995). "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis." <u>J Clin Invest</u> 95(4): 1789-97.	
	C60	Wilcox, J. N., K. M. Smith, et al. (1988). "Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization." J Clin Invest 82(3): 1134-43.	
	C61	Wilkinson, D. 2000. "Ultimate Abs: Immunochemical techniques inspire development of new antibody purification methods." The Scientist. 14(8): 25-28.	
	C62	Wozney, et al., 1988 "Novel regulators of bone formation: molecular clones and activities." Science 242(4885): 1528-1534. GenBank Accession Number: PIR-ID:A58788	
	C63	Wozney, J. M., V. Rosen, et al. (1988). "Novel regulators of bone formation: molecular clones and activities." Science 242(4885): 1528-34.	
	C64	Yamada, et al., "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D." Genomics: 42:483-488. GenBank Accession Number: 035251	
	C65	Yoshikawa, H., K. Takaoka, et al. (1985). "Clinical significance of bone morphogenetic activity in osteosarcoma. A study of 20 cases." Cancer 56(7): 1682-7.	
V	C66	Yuan, F., Y. Chen, et al. (1996). "Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody." Proc Natl Acad Sci U S A 93(25): 14765-70.	

* a copy of th	is reference is not provid	ed as it was previous	ly cited by or submitted to the	e office in a prior application,
Serial No	, filed		_, and relied upon for an ear	lier filing date under
35 U.S.C. §1:	20 (continuation, continua	ation-in-part, and divi	sional applications).	
Γ	1	$\overline{}$		
Examiner		// <	Date	11/ //
Signature	1 Dona	rana	Considered	11/26/01
		11000		
EXAMINER: I	nitial if reference conside	red whether or not o	itation is in conformance with	MPEP 609: Draw line through

EXAMINER: Initial if reference considered, whether or not citatic citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADOCS:1414016.1(%B2801!.DOC)